Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (109)
Cancellation by sponsor (70)
Prescription medicine registration (56)
Australian public assessment report (AusPar) (46)
Designation or determination (23)
Prescription medicine decision summary (11)
Prescription medicine evaluation (7)
Section 14, TGO91 consent (1)

Date

2026 (1)
2025 (32)
2024 (28)
2023 (31)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (6)
2012 (3)
2011 (5)
2010 (4)
2008 (3)
2006 (5)
2004 (2)
2003 (5)
2002 (2)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Search

Sponsor content

323 result(s) found, displaying 191 to 200

FORXIGA (AstraZeneca Pty Ltd)

15 April 2020

Prescription medicine registration

Active ingredients: dapagliflozin propanediol monohydrate.
XIGDUO XR (AstraZeneca Pty Ltd)

15 April 2020

Prescription medicine registration

Active ingredients: dapagliflozin propanediol monohydrate; metformin hydrochloride.
AusPAR: Acalabrutinib

10 March 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Acalabrutinib
AusPAR: Acalabrutinib

3 March 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Acalabrutinib
Calquence

13 December 2019

Prescription medicine decision summary

Australian prescription medicine decision summary
CALQUENCE (AstraZeneca Pty Ltd)

22 November 2019

Prescription medicine registration

Active ingredients: acalabrutinib.
CALQUENCE (AstraZeneca Pty Ltd)

21 November 2019

Prescription medicine registration

Active ingredients: acalabrutinib.
AusPAR: Olaparib

30 October 2019

Australian public assessment report (AusPar)

Australian Public Assessment Report for Olaparib
Notice for moxetumomab pasudotox (AstraZeneca Pty Ltd)

25 September 2019

Designation or determination

Orphan drug
AusPAR: Osimertinib mesilate

24 September 2019

Australian public assessment report (AusPar)

Australian Public Assessment Report for Osimertinib mesilate

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.